We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ONT Oxford Nanopore Technologies Plc

-2.10 (-2.16%)
Last Updated: 12:40:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Nanopore Technologies Plc LSE:ONT London Ordinary Share GB00BP6S8Z30 ORD GBP0.0001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.10 -2.16% 95.25 95.25 95.70 97.40 94.80 97.40 194,502 12:40:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 169.67M -154.51M -0.1798 -5.27 814.81M
Oxford Nanopore Technologies Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker ONT. The last closing price for Oxford Nanopore Technolo... was 97.35p. Over the last year, Oxford Nanopore Technolo... shares have traded in a share price range of 91.50p to 279.00p.

Oxford Nanopore Technolo... currently has 859,503,324 shares in issue. The market capitalisation of Oxford Nanopore Technolo... is £814.81 million. Oxford Nanopore Technolo... has a price to earnings ratio (PE ratio) of -5.27.

Oxford Nanopore Technolo... Share Discussion Threads

Showing 3226 to 3250 of 3250 messages
Chat Pages: 130  129  128  127  126  125  124  123  122  121  120  119  Older
Most of the presentations from LC2024 uploaded now, of particular interest are those from the Clinical Day. Gordon Sanghera suggested that commercial traction from clinical applications will begin in 2025, providing an alternative income stream for ONT.


A prospective clinical pilot study was conducted in ICU patients with respiratory failure, using a unified respiratory metagenomic (RMg) workflow encompassing DNA and RNA sequencing.

Respiratory metagenomics in clinical service

PulseNet — the national molecular surveillance network of over 80 public health labs in the United States, connects food, water, and one-health related illnesses that may be part of an outbreak —fully implemented WGS in 2019. WGS data is comprehensive: antimicrobial resistance, virulence markers, serotype markers, plasmids, and core and accessory genes are all characterized as part of the WGS workflow. Additionally, sequence data is portable and is shared between United States federal agencies, over 80 PulseNet International member countries, and public repositories, including the National Center for Biotechnology Information (NCBI). Currently, PulseNet USA sequences approximately 65,000 Salmonella, Escherichia, Listeria, Vibrio, Campylobacter, and Shigella isolates annually.

Whole-genome sequencing in PulseNet foodborne molecular surveillance systems

Vid from recent Genomics England event.
Empowering comprehensive sequencing at scale [with Greg Elgar]

Better off waiting for confirmation on the turn, miss the first 15%?
Still can't seem to find any safe bottom to enter here - will have to be super patient indeed. American rival share price still rather sour - does not help sentiment... nai etc
Wise words.
Unfortubtaley it looks like the. Next move might be downwards unless revenues and evidence and ebita pick up dramatically. In this sector with everyone struggling with funding and cutting back customers are likely to hold back which won't help ONT

Happy to watch for now and see how fast the cash is being spent. They need to either massively increase revenue or look to cut costs and keep that cash in these times

Take it easy, I've been out of these for a couple of weeks now as the share reconsolidates at the £ level. Worth watching or accumulating as I think the outer will come quickly one way or another.
Uses Nanopore

Laura Foster BBC News, Thetford Forest

Scientists sampling DNA in the air to monitor the spread of deadly diseases said their work could help make food prices cheaper.

The Earlham Institute said its air sampler processes detect bacteria, viruses and other micro-organisms - which pose a threat to plants, animals and humans - more quickly and accurately than other techniques.

This could help farmers grow crops more cheaply and efficiently as they would not need to use as many chemicals.

It could also transform environmental conservation work as well as public health measures.


Much work going on in the rest of Europe on this topic.

"Environmental microbiome diversity and stability is a barrier to antimicrobial resistance gene accumulation"

The most significant detractors to performance in the period were Ocado, Alnylam and Oxford Nanopore.

Oxford Nanopore flagged that tepid academic research budget growth, alongside a curtailing of its UAE genome sequencing project, would act as a drag on 2024 revenue growth. These issues as unhelpful but transient. Ultimately, they distract from what we think is the compelling evidence building to support its novel technology in clinical and applied sequencing use-cases, previously off- limits to DNA sequencing from a cost or practicality perspective. The company has an increasing pool of industry partners and collaborators with whom it is looking to develop new applications eg Biomerieux in antimicrobial resistance, Lonza in quality testing of mRNA therapeutics and Guy's & Thomas' NHS Trust to investigate rapid identification and analysis of pathogens in intensive care units. In time, such opportunities could support a market opportunity far bigger for DNA analysis than that currently represented by the conventional academic-skewed research market.

BG EWI IT assessment of ONT as a top 10 holding in their financial reports yesterday.

They are being careful in their language - "could" rather than "will" plenty of uncertainty around great possibilities etc :) dyor etc

I do pop in every now and again here, waiting and waiting for a time to join in but even with these steep falls this market sector arguably with high interest rates not helping the cause is struggling across the board.

Will read the link above and see the firm's take on the future.

But we clearly have yet to find a proper support and downtrend pattern remains ongoing.

nai etc

Oxford Nanopore’s Clive Brown Looks Back and Ahead June 4, 2024
ONT at ESHG today, this is the agenda for discussion,

Such is the interest in ONT kit, it's standing room only again. This was the situation at LC2024 too. Let's hope the newly expanded sales team can make something out of this interest, and next months outlook is back to expectations.

GRAIL is toast in the UK. It's expensive, [$900+] innacurate and unhelpful to the cause of liquid biopsy as a worthwhile endeavour.


NHSE will not extend high-profile cancer test pilot

By Ben Clover30 May 2024

NHS England has decided not to extend the ongoing pilot of a high-profile emerging cancer screening technology, casting further doubt on its target to improve early detection.


Thankfully common-sense has won the day. Grail's [Illumina] test was a poor performer, and relied on spotting later stage cancers. The whole point of Liquid biopsy HAS to be detection of a wide range of different cancers at stage 0 or 1.

Daniel Kim is successfully experimenting using ONT kit and RNA sequencing to find the stage 0/1 cancers.

Confident directors here spent half a million pounds on shares in March.
21 May 2024

A team of researchers, including from the Institute of Environmental Science and Research (ESR) and Awanui Labs Wellington, have successfully implemented a Nanopore genomic surveillance system that enabled the early detection and control of a Clostridioides difficile (C. difficile) infection outbreak in a ward of a Wellington-based hospital. The open access findings, described in the journal Infection Control & Hospital Epidemiology, highlight several novel aspects of this approach that could significantly impact future clinical practices.

By prospectively using genomic sequencing, the team was able to identify and manage the C. difficile outbreak at a relatively early stage, demonstrating the potential for such methods to improve patient outcomes and reduce the spread of infections, ultimately making the hospital a safer place for patients. C difficile is a serious bacterial infection of the colon and intestines, which mostly affects people in hospitals.

Disappointing price action given the good progress at the company. I note INOV are still selling down their holding (you can't blame them as they are using the cash to buy back shares at an excess of 50% nav discount - so they are effectively arbitraging) and there must be other large holders selling in to any strength. Time will tell.
Oxford Nanopore Technologies Eyes TB Test as First In-House-Developed Diagnostic Test

May 23, 2024 | Huanjia Zhang

Please use link for whole article.

NEW YORK – Oxford Nanopore Technologies has been working on a tuberculosis drug resistance sequencing assay that it hopes will become its first in vitro diagnostic test developed in house.

Dubbed Ampore-TB, the assay will enable TB drug resistance profiling directly ̴3;from sputum samples in about six hours using the GridIon platform and an automated analysis pipeline supported by Epi2me, Oxford Nanopore’s cloud-based bioinformatics platform.

An Oxford Nanopore spokesperson told GenomeWeb that Ampore-TB is currently undergoing internal validation and is slated to be released globally as a research-use-only product later this year. The company plans to obtain regulatory approval for the test under the European Union’s In Vitro Diagnostic Regulation and from the US Food and Drug Administration but did not disclose a timeline.

The GridIon platform will meet the ISO 13485 standard in 2025, the spokesperson also noted, but that instrument will not be specific to TB testing and will only be available to specified partners.

According to Emma Stanton, senior VP of clinical at Oxford Nanopore, a major reason for the company to select Ampore-TB as its first prospective IVD test is "a very clear call to action" from the World Health Organization, which published a new guideline in March recommending the use of targeted next-generation sequencing for the diagnosis of drug-resistant TB.

The guideline specifically highlighted Oxford Nanopore’s Ampore-TB, along with the Deeplex Myc-TB test from Genoscreen in France and the Tbseq assay from Hangzhou ShengTing Medical Technology in China.

Oxford Nanopore has yet to disclose Ampore-TB’s technical specs. Stanton declined to comment on the final format of the assay, citing the early stage of its development.

According to the WHO’s guideline, Ampore-TB, which analyzes sputum samples, is a targeted NGS test developed for the simultaneous identification of mycobacterial species and the detection of mycobacterium tuberculosis (MTBC) complex genetic variants that have been linked to antimicrobial resistance. The guideline noted that Ampore-TB has met the performance criteria to profile resistance to rifampicin, isoniazid, fluoroquinolones, linezolid, amikacin, and streptomycin.

The assay sequences 27 amplicons, including 24 drug resistance targets, a genotyping target, a non-tuberculous mycobacteria identification target (hsp65), and an internal control, using the Oxford Nanopore GridIon device.

Additionally, the guideline noted that the Ampore-TB workflow includes pre-installed analysis software that can automatically generate a report of the test results.

Stanton said Ampore-TB is being developed by Oxford Nanopore internally, with some IP licensed from the UK's Quadram Institute, which the company has been collaborating with to develop the workflow. Once the test is ready, Oxford Nanopore plans to leverage its existing partnership with French in vitro diagnostics firm BioMérieux to help roll it out globally, tapping into the partner's logistics network.

"[BioMérieux’s] role is in helping us to commercialize and distribute the test, they are not developing the test," said Stanton. "Essentially, we will give them the fully developed test, and they will be responsible for distributing it."

"After a year-long partnership with Oxford Nanopore, significant progress has been made towards developing a research use only (RUO) sequencing product for detecting drug resistance in tuberculosis," Charles Cooper, executive VP and chief medical officer of BioMérieux, wrote in an email. "This achievement results from an excellent collaboration between the teams involved. It marks an important milestone in the development of an in vitro diagnostic (IVD) test."

While Cooper’s statement appears to suggest BioMérieux is involved in the development of Ampore-TB, an Oxford Nanopore spokesperson confirmed that the test is completely developed in house by the company. The spokesperson also said BioMérieux is "sharing their indispensable experience on infectious disease diagnostics" with Oxford Nanopore.

Stanton said Oxford Nanopore will have to get regulatory approval from each of the countries it plans to sell Ampore-TB in. The goal is to launch the test in waves, she said, and her team has already begun conversations with regulatory authorities of those countries where the test will first become available.

She did not disclose the names of those countries and did not comment on Oxford Nanopore's plans for regulatory approvals in low- and middle-income countries, where TB testing is in highest demand.

Ampore-TB is not the only sequencing-based TB test highlighted by the WHO. The TBseq test from China’s Hangzhou ShengTing Medical Technology, for instance, also uses the Oxford Nanopore MinIon or GridIon platform. Meanwhile, Genoscreen’s Deeplex Myc-TB can be performed using the Nextera XT and DNA lex library preparation kits and the Illumina iSeq 100, MiniSeq, MiSeq, or NextSeq sequencers, according to the guidelines.

Besides the advantages of nanopore sequencing forTB testing, such as its fast turnaround time and accessibility, the WHO guideline also pointed out some "feasibility challenges" for the technology, including library preparation being "quite complex" and "the need for improved computer analysis and storage capacity."

Beyond targeted NGS, WHO’s guideline also highlighted various other molecular technologies for rapid TB diagnosis and resistance detection, including moderate-complexity automated nucleic acid amplification technologies (NAATs) for the detection of TB and resistance to rifampicin and isoniazid, lateral flow antigen detection tests, low-complexity automated NAATs for the detection of resistance to isoniazid and second-line anti-TB agents, and line-probe assays.

The development of Ampore-TB is spearheaded by Oxford Nanopore Diagnostics, a subsidiary of Oxford Nanopore that was established in 2022 but has largely remained silent since then.

"We haven't spoken about [OND] a lot in the public domain," said Stanton, who heads the subsidiary. While the creation of OND was "necessary for many legal, contractual, and regulatory requirements," she said, her team is "deliberately embedded across in the parent organization" and works closely with the rest of company.

According to Stanton, the OND team includes people working in regulatory affairs and quality assurance. It also has employees with "domain expertise" across various clinical areas, as well as "other people who [have] experience from our competitors in taking sequencing platforms into clinical markets," she added.

Beyond its in-house development efforts, Stanton said an integral part of Oxford Nanopore’s clinical strategy is to forge partnerships with other institutions and companies. Although Ampore-TB is on track to become the company’s first own IVD product, infectious disease is "the smallest target addressable market" for the firm, she said, adding that the company is also eyeing other disease areas such as oncology, transplant diagnostics, as well as rare diseases and other genetic disorders.

Stanton highlighted a series of clinical partnerships the firm has already forged, such as an agreement with Day Zero Diagnostics to develop a diagnostic solution for sepsis, collaborations with Hungarian firm Omixon and Dutch company GenDx to develop HLA transplant diagnostic tests, and a deal with Swiss manufacturer 4bases to develop tests for BRCA1 and BRCA2 breast and ovarian cancer susceptibility genes.

At its annual user meeting in London this week, Oxford Nanopore is holding a dedicated 'Clinical and Biopharma Day' for the first time that is distinct from the main event, signaling the company’s increasing focus on clinical and applied markets

Still, with Ampore-TB’s IVD timeline unclear, it appears that Oxford Nanopore has a way to go to become a diagnostic test manufacturer.

"Whilst we are on a path to have diagnostics, this is really about showcasing and sharing where we are [with the technology]," Stanton said. "It's a Clinical and Biopharma Day, not a Diagnostics Day, quite deliberately."

janeann, welcome. This has to be one of the most exciting co's in the UK right now.

Suggest you search Nanopore on twitter, where you can follow many of ONT's customers, and read the thread. More recently I have tried to focus on posting material that is written in laymans terms, as some of processes and advanced biology is challenging. There are numerous online courses and info that allow you to brush up on genetics and sequencing basics. Surprisingly, the NHS website has a good introduction, with a slant towards clinical uses.

Joined you here bamboo.....bought afew early yesterday and a few more today. I think i generally buy new tech shares too early ... hopefullythis time will be about right!!
Need to better understand the application of the technology now

MinION Mk1D: The next generation of portable sequencing
Vid of the tech update from last night.
London Calling Technology Update

Announcements highlighted breakthrough technology performance and updates to Oxford Nanopore's IVD pipeline at annual customer conference

23 May 2024

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the "Company"), the company delivering a new generation of nanopore-based molecular sensing technology, presented breakthrough performance data and new platform updates at the Company's annual London Calling customer conference, held between 21 and 24 May 2024. During the sold-out event, with more than 5,500 registered on-line and in-person participants, the Company also provided updates to its clinical product pipeline, unveiling a new roadmap for its first IVD product ahead of its first clinical and biopharma day on Friday.

Technology updates included:

· Delivering increasingly rich, high performance multiomic data: The update focused on improved performance on accuracy, delivering complete genomes with nanopore-only Telomere-to-Telomere (T2T) sequencing, and full-length chromosomes in a single read, illustrated by successful T2T reads of four yeast chromosomes as proof of concept.

· Improving direct RNA sequencing to support breakthrough science and biopharma workflows: higher accuracy and output for direct RNA sequencing alongside the example of integrated, real-time quality control (QC) test for mRNA vaccines.

· Pipeline updates, enabling ultra-high output and accessible, distributed sequencing for anyone, anywhere: with the MinION Mk1D entering early access, continued progression with TraxION, enabling portable library prep in the field, the Voltage chip for ultra-rapid whole genome sequencing (WGS) and the new prototype of Oxford Nanopore's smallest sequencer to date - the SmidgION - which was on display at the event.

A written summary and a video replay of the technology talk can be accessed on the Oxford Nanopore website here.

This morning, the Company will present a product review including an update on progress to its regulated product pipeline. In addition to locked-down Q line devices, the GridION is expected to meet ISO 13485 standards in 2025 and the Company will seek CE-IVD certification in the EU after that. The device will be available for specified partners only. The GridION Q-Line product range is on track to launch shortly in Q3-2024, as previously announced.

Alongside the technology updates the Company will also provide more details at its first clinical and biopharma day on Friday.

Illumina can't buy ONT.

They already tried that with Pacb, and got stopped by anti-trust regs. This also means an agreement or partnership between ONT and either of the other two players is very unlikely.

There are however numerous other potential suitors around the world.

For me the number one thought is that BioMerieux made a partnership and began work in Apr 23 approx, then after having had 6 months to evaluate they made their further agreement and bought equity in Oct 23, so they must have liked what they saw in terms of potential following their initial collaboration.

Also, when LAT expires should qualify for FTSE 250 meaning qualify for inclusion in more funds and inv trusts

magnum opus
BioMerieux hands are tied by the lockout at 9.9% so can buy another 3% which may well be starting to happen. As I see it, Illumina also wants Oxford Nano to complement and enhance its own tech. It, and likely others will start to show their hands anytime as the overall takeover protection afforded at IPO expires in June. BM is barred from making an offer 'unless a third party enters the arena' like Illumina......then the gloves are off and BioMerieux can bid. Given the depth and exposure of involvement in joint projects with ONT, it is foolish to believe that BM would want to win the prize given its financial clout.Interesting times ahead given the potential for truly explosive growth here imo.
BioMerieux Mcap is 11.8 bln. They will be looking to snap up ONT or merge imo. They bought a substantial amount of ONT in October at twice this price. No smoke without fire. BUY

Also with LAT shares expiring June these are going to rerate. Buy now and hold this could easily go up 200% this year.

We all have an opportunity to buy at these ridiculously cheap levels.

Chat Pages: 130  129  128  127  126  125  124  123  122  121  120  119  Older

Your Recent History

Delayed Upgrade Clock